Clinical evaluation of anlotinib in third-line treatment for advanced non-small cell lung cancer based on real-world data
- VernacularTitle:基于真实世界数据的安罗替尼三线治疗晚期非小细胞肺癌的临床评价
- Author:
Jian WU
1
;
Peipei LI
1
;
Yongfu ZHU
2
;
Dongwei ZHANG
2
;
Yongzhong WANG
1
;
Hao CHEN
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Anhui University of Chinese Medicine，Hefei 230031，China
2. Dept. of Medical Oncology，the First Affiliated Hospital of Anhui University of Chinese Medicine，Hefei 230031，China
- Publication Type:Journal Article
- Keywords:
anlotinib;
advanced non-small cell lung
- From:
China Pharmacy
2025;36(12):1488-1494
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the clinical value of anlotinib in third-line treatment for patients with advanced non-small cell lung cancer （NSCLC） through real-world data. METHODS Clinical data of patients with advanced NSCLC who received treatment at the First Affiliated Hospital of Anhui University of Chinese Medicine from February 2021 to December 2024 were retrospectively collected. They were divided into anlotinib group （27 cases， receiving anlotinib therapy） and immunotherapy group （22 cases， receiving immunotherapy agents alone or in combination with chemotherapy drugs） according to treatment regimens. The progression-free survival （PFS） and overall survival （OS） of patients were compared between the two groups， and the occurrence of adverse drug reactions during the treatment period was recorded. Using a partitioned survival model， an economic evaluation of the two treatment regimens was conducted with a cost-utility analysis approach from the perspective of the healthcare system. RESULTS The median PFS and OS of patients in the anlotinib group were 5.93 months and 11.27 months， respectively； the median PFS and OS of patients in the immunotherapy group were 5.33 months and 9.77 months， respectively； the difference was not statistically significant （P＞0.05）. There was no statistical difference in the total incidence of adverse drug reactions and grade 3-4 serious adverse drug reactions between the two groups （P＞0.05）. Compared with the immunotherapy group， the incremental cost-effectiveness ratio of the anlotinib group was 1 806 724.60 yuan/quality-adjusted life year （QALY）， which was significantly higher than three times China’s per capita gross domestic product in 2024 （287 247 yuan/QALY）. CONCLUSIONS For third-line treatment of advanced NSCLC patients， the efficacy of anlotinib is no worse than that of immunotherapy alone or in combination with chemotherapy drugs， and the safety of the two groups is comparable. However， anlotinib is not cost-effective.
